Exelixis · Health Care
EXEL
$55.92
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of...Exelixis,Inc.是一家位于加利福尼亚州阿拉米达的基因组学药物研发公司，其产品Cometriq已获美国食品药品监督管理局批准用于治疗甲状腺髓样癌，并对多种其他类型转移性癌症具有临床活性。
Secular growth长期成长
Large cap大盘
$15B
Engine stance引擎立场2026-07-20
Lagging — relative weakness落后 — 相对弱势
The bottoming setup is not yet confirmed (price still below the 10-day average) and the daily momentum is already rollin筑底形态尚未确认（价格仍位于 10 日均线下方），且日线动量已开始掉头向下——动量在形态完成前已开始衰竭。等待价格收复 10 日均线且动量趋于稳定后再考虑建仓。
Key Statistics关键统计
Price价格
$55.92
2.1% below 52-week high低于52周高点 2.1%
Market Cap市值
$15B
Normal volume正常成交量
P/E Ratio市盈率
18.8x
28.9x sector median
Beta贝塔
0.58
Moves about 0.6x the market波动幅度约为市场的 0.6 倍
RSI (14)RSI（14）
60
Elevated偏高
Next Earnings下次财报
2026-07-27 (8d)
Volatility Rank波动率分位
14th pctile
hist. vol. percentile历史波动率分位数
Short Interest空头兴趣
10.9% of float
Performance价格表现
| Period周期 | EXEL | S&P 500 | vs Index对比指数 |
|---|---|---|---|
| 1 Week近1周 | -1.0% | -1.5% | In line with the index与指数基本持平 |
| 1 Month近1月 | +6.6% | +0.6% | Beat the index by 6.0 points跑赢指数 6.0 个百分点 |
| 3 Months近3月 | +24.6% | +4.7% | Beat the index by 19.9 points跑赢指数 19.9 个百分点 |
| 6 Months近6月 | +27.2% | +7.8% | Beat the index by 19.4 points跑赢指数 19.4 个百分点 |
| Year to date年初至今 | +28.3% | +9.1% | Beat the index by 19.2 points跑赢指数 19.2 个百分点 |
| 1 Year近1年 | +24.6% | +19.4% | Beat the index by 5.2 points跑赢指数 5.2 个百分点 |
| 3 Years近3年 | +189.7% | +69.4% | Beat the index by 120.3 points跑赢指数 120.3 个百分点 |
Technicals技术面
RSI (14)RSI（14）
60
Elevated偏高
vs 50-day相对50日均线
+6.8% vs 50-day avg
vs 200-day相对200日均线
+24.3% vs 200-day avg
Volatility rank波动率分位
14th percentile 分位
Engine reference levels — not advice引擎参考水平 — 非投资建议
Buy zone买入区间
$54.76
Don't chase above不追高于
$55.92
Stop止损
$51.34
Extended — wait for a pullback过度拉伸 — 等待回撤
Earnings财务业绩
8
days until next report天后公布财报
2026-07-27
Estimates being cut预期下调
Earnings call transcripts — coming soon财报电话会议记录 — 即将上线
Valuation估值
| Multiple指标 | EXEL | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（历史） | 18.76x | 28.92 | 77% |
| P/B市净率 | 6.79x | 3.52 | 21% |
| P/S市销率 | 6.33x | 3.02 | 22% |
| Earnings yield盈利收益率 | 5.33% | 2.72 | 83% |
| FCF yield自由现金流收益率 | 5.97% | 3.94 | 77% |
| Shareholder yield股东收益率 | 6.46% | 1.89 | 87% |
| EV/EBITDA企业价值/EBITDA | 15.75x | 18.21 | 60% |
| P/FCF市值/自由现金流 | 16.76x | 22.42 | 73% |
Analyst price targets — coming soon分析师目标价 — 即将上线
Financials财务数据
Revenue营业收入
5yr CAGR5年复合增速: 18.6%
Earnings Per Share每股收益
5yr CAGR5年复合增速: 51.4%
Free Cash Flow自由现金流
Margins利润率
36.2%Return on Equity股本回报率
27.5%Return on Assets资产回报率
Leverage杠杆
| Net debt / EBITDA净债务/EBITDA | -0.54 |
| Current ratio流动比率 | 3.56 |
Capital Allocation资本配置
| Buybacks (TTM)回购（TTM） | $947.5M |
| Stock-based comp股权薪酬 | $113.0M |
| Share count change (1y)股数变化（1年） | -6.8% |
Piotroski皮奥特罗斯基 6/8
Altman Z阿尔特曼Z: safe (15.1)
Clean稳健
Snapshot Gauges综合指标
Valuation vs Sector估值相对行业
Roughly fair vs sector相对行业估值合理
Cheaper than 51% of its sector on blended multiples综合估值倍数低于行业内 51% 的公司
Beta市场敏感度
0.58×
0.21×3×
Moves about 0.6× the market波动幅度约为市场的 0.6 倍
Financial Health财务健康
6/8
Altman阿尔特曼: safe
Adequate financial health财务健康状况一般
Dividend分红
—
Does not pay a dividend不派发股息
Why Is It Moving为何波动
Macro宏观
Long-duration name into a restrictive, rising-real-rate regime → rate headwind.长久期标的进入偏紧、实际利率上行的环境→利率逆风。
Positioning持仓
Insider cluster activity内部人集中交易
Technical技术面
EXEL daily MACD crossed downEXEL 日线MACD下穿
Ownership & Smart Money持仓与聪明钱
Insider activity内部人员活动: -$29.9M net (1 buyers, 10 sellers)-$29.9M 净值（1 买家，10 卖家）
Signal History信号历史
TURN SIGNALED
BOTTOMING
Jul 15, 2026
EXEL daily MACD crossed downEXEL 日线MACD下穿
The daily MACD histogram turned negative — fast and noisy, context rather than a standalone trigger. $55.55.日线MACD柱状图转负 — 快速且嘈杂，仅作背景。$55.55。
Jul 9, 2026
EXEL made a new 52-week highEXEL 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $57.10.价格创出52周新高 — 全市场关注的动量/趋势极值。$57.10。
Jul 7, 2026
BOTTOMING → NEARING A HIGH筑底中 → 接近高点
TAKE PROFITS止盈
Jul 7, 2026
EXEL made a new 52-week highEXEL 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $57.08.价格创出52周新高 — 全市场关注的动量/趋势极值。$57.08。
Jul 6, 2026
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP买入预备
Jul 2, 2026
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP买入预备
Jul 2, 2026
EXEL made a new 52-week highEXEL 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $55.85.价格创出52周新高 — 全市场关注的动量/趋势极值。$55.85。
Jun 29, 2026
EXEL daily MACD crossed upEXEL 日线MACD上穿
The daily MACD histogram turned positive — fast and noisy, context rather than a standalone trigger. $54.28.日线MACD柱状图转正 — 快速且嘈杂，仅作背景。$54.28。
Jun 26, 2026
EXEL made a new 52-week highEXEL 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $54.77.价格创出52周新高 — 全市场关注的动量/趋势极值。$54.77。
Showing last 15 of显示最近15条，共 277 signals条信号
Factor Profile因子特征
Composite factor score综合因子得分: 0.15
Value价值
-0.6
Quality质量
+0.0
Investment资本投入
+0.7
Shareholder payout股东回报
+0.6
Low volatility低波动
-0.0
Low market beta低市场敏感度
+0.4
Earnings quality盈利质量
-0.2
Short interest空头兴趣
-2.1
Company Profile公司档案
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of...Exelixis,Inc.是一家位于加利福尼亚州阿拉米达的基因组学药物研发公司，其产品Cometriq已获美国食品药品监督管理局批准用于治疗甲状腺髓样癌，并对多种其他类型转移性癌症具有临床活性。
Watch items — what could change the thesis关注项 — 可能改变论点的因素
- Margin compression despite revenue growth
Get the full picture获取完整视图
Nightly signals, options flow, and factor analysis across all S&P 500 names.每日更新的信号、期权资金流向和因子分析，覆盖所有标普500成分股。